Celsion Corporation (NASDAQ:CLSN) Q3 Results Disappoint

Celsion Corporation (NASDAQ:CLSN)

Shares of Celsion Corporation (NASDAQ:CLSN) fell 5.2% after the oncology drug development company reported financial results for the three and nine months ended September 30, 2017. A net loss for the two periods appears to have spooked the market, fuelling a sell-off of the stock.

Celsion Corporation (NASDAQ:CLSN)

CLSN Sell-Off

Following Tuesday’s sell-off, Celsion Corporation (NASDAQ:CLSN) is at risk of dropping to this year’s lows as it continues to trade in a strong downtrend. The stock has shed more than 50% in market value since the start of the year as investors continue to question the company’s long-term prospects.

However, data compiled by Zacks Investment Research indicates that two analyst firms currently rate the stock as a ‘strong buy’ amidst the growing short interest. Despite disappointing financial results, analysts are forecasting a 76.6% year over year increase in earnings. The analysts also expect earnings to grow by 48.4% next year.

For the quarter ended September 30, 2017, Celsion Corporation (NASDAQ:CLSN) reported a net loss of (-$5.7) million or (-$0.70) a share compared to a net loss of (-$6.4) million reported last year. The company attributes the decrease to a tighter clinical development focus coupled with lower operational expenses. Net loss for the first nine months came in at (-$16.1) million compared to (-$16.7) million as of last year.

Celsion Pipeline Development

During the quarter Celsion Corporation (NASDAQ:CLSN) recognized deemed dividends totaling $0.4 million with regards to multiple agreements with certain warrant holders. The company also made important milestones in the development of its lead clinical programs and capital infusion of $38 million to help drive the development efforts.

Celsion Corporation (NASDAQ:CLSN) is currently working on ThermoDox, its proprietary heat-activated liposomal encapsulation currently in Phase III for the treatment of primary liver cancer. The company’s immunotherapy program consisting of GEN-1 is currently in Phase 1 development as a localized treatment for Ovarian Cancer.

“We believe that we now have sufficient capital to complete enrollment of our Phase III OPTIMA Study and through the first efficacy analysis expected in the first quarter of 2019. Further, we expect that our current funds will allow us to make substantial progress in our open-label, randomized, 86 patient Phase I/II study of GEN-1 in newly diagnosed stage III and IV ovarian cancer patients,” said CEO, Michael Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) Dilutes Shareholders – Again

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) shares dropped nearly 20% after the biotechnology firm announced the pricing of an underwritten offering of 2,640,000 shares of its common stock and warrants. The offering prices 1.32 million CLSN shares at $2.50 and each share is is being sold together with 0.50 warrants, with each whole warrant exercisable to purchase one whole share of common stock. The warrants have an exercise price of $3.00 per share, are not exercisable until six months after issuance and will terminate 5 years from the time each warrant is first exercisable. Celsion expects to raise $6.6 million before expenses and fees are deducted.

Celsion Corporation (NASDAQ:CLSN)

The announcement sent the shares gapping lower to open at $2.30 after closing on Thursday at $2.86. Twice during October CLSN stock had made runs to the $6 handle before retreating. Prior to Friday, the shares had experienced over ten trading days of consecutive losses.

Lawrenceville, NJ-based Celsion Corporation (NASDAQ:CLSN) is an oncology drug company that develops and commercializes directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.

CLSN Stock Performance

On October 4, 2017 Maxim Group upgraded their rating on CLSN shares from a “Hold” to a “Buy” with a $7 price target. Two other investment firms have previously rated CLSN stock as a “Strong Buy”. The one-year consensus price target is $8.

However, shares of the biotech have not performed. Year-to-date shares are down over 45% and are down over 84% for the year. In the short-term shareholders have seen a bounce from the August-September trading range under $2 and their monthly performance is a positive 50% over the past month.

Celsion Corporation (NASDAQ:CLSN) has a consistent history of issuing shares and diluting shareholder equity. In 2012, there were 550,000 shares outstanding and that number has grown each year. In 2016 there were 1.85 million CLSN shares outstanding. Earnings have been just as frustrating for shareholders. Per share losses have been reported every year since 2012 and for 2016 the loss was (-$11.90) per share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) Struggles To Close Above $6

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) shares fell 1.69% after initially rising by 8% in pre-market trading, after the company announced the publication of a manuscript for its Phase III HEAT study, assessing ThermoDox in hepatocellular carcinoma (HCC). The article details findings from a study of 701 patients as well as results from computer simulation studies.

ThermoDox Development

ThermoDox is Celsion’s most advanced tumor-targeting drug delivery technology and employs a novel heat-sensitive liposome to address difficult-to-treat cancers. The program is currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.

“We believe strongly that ThermoDox® may be an important new approach for the treatment of HCC. We are now fully committed to the OPTIMA Study and to learning more about how this combination therapy of standardized RFA plus ThermoDox® may significantly prolong the survival of, if not cure, patients,” said CEO Michael H. Trading.

Celsion Corporation (NASDAQ:CLSN)’s upside run, that began early in the month, is losing its momentum. The stock has struggled to close above the $6 a share on two attempts. Selling pressure appears to be slowly building. The stock has underperformed the industry for the better part of the year and the stock continues to trade at levels last seen in January.

The stock is currently rated as a ‘strong buy’ by two firms and as a ‘hold’ by one firm according to data compiled by Zack Investment Research.

Celsion’s New Financing

Celsion Corporation (NASDAQ:CLSN)

Separately, Celsion Corporation (NASDAQ:CLSN) has entered into Exercise agreements with holders of existing warrants issued in July. Pursuant to the agreement, the company has agreed to issue 2.4 million Series AAA Warrants at an exercise price of $2.07 a share and series BBB Warrants are an exercise price of $4.75 a share.

Celsion Corporation (NASDAQ:CLSN) expects gross proceeds of $15.6 million from the exercise of the Series AAA and Series BBB Warrants. Net proceeds are to be used for general corporate purposes. According to CEO, Michael Trading, the exercise agreements eliminate financial challenges that the company has faced in recent years. The executive also expects the new financing to help accelerate the development of drug candidates in the company’s pipeline.

“This significant capital infusion from the exercise of existing outstanding warrants at their original exercise prices is an example of our strategic approach to financing and is expected to extend the Company’s operating horizon through full patient enrollment of our Phase III OPTIMA Study,” said Mr.  Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Celsion Corporation (NASDAQ:CLSN)

Brief Uptick for Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) stock was slightly higher today on the company’s announcement of positive data findings from its Phase Ib dose escalating clinical trial for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer. CLSN volume was over three times the listed average as the stock price ended the day at $1.75.

Celsion Corporation (NASDAQ:CLSN)
One month daily candlebar chart for CLSN

Ovarian cancer is the most lethal of gynecological malignancies among women, with an overall 5-year survival rate of 45%. There were approximately 22,000 new cases of ovarian cancer in the United States in 2014 with an estimated 14,000 deaths. Mortality rates for ovarian cancer declined very little in the last 40 years, due to lack of early detection tests and little improvement in treatments

Lawrenceville, NJ-based Celsion Corporation (NASDAQ:CLSN) is an oncology drug company that develops and commercializes directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. Celsiuon’s lead products include ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Shares of Celsion Corporation (NASDAQ:CLSN) have been under pressure for some time. Almost 18% of the stock’s float is held by short-sellers. Since 2012, shareholders have experienced an annual per share loss. Adjusted for dilution, in 2012 the per share loss was (-$48.11) and that loss shrank in 2016 to (-$11.90). However, the number of shares outstanding continues to increase annually. In 2012 there were 550,000 shares outstanding and by 2016 that number grew to 1.85 million.

CLSN stock is down nearly 60% YTS and down nearly 90% for the year. What is noteworthy is that despite the company’s stock struggles in the market, two of the three analysts that follow the firm rate the shares a “Strong Buy” – one rates the shares a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Celsion Corporation (NASDAQ:CLSN)

Update on Celsion Corporation (NASDAQ:CLSN) Sends Shares Booming!

Celsion Corporation (NASDAQ:CLSN)

Shares of Lawrenceville, NJ-based Celsion Corporation (NASDAQ:CLSN) are up over 36% in the first hour of trading. Volumes are extraordinarily heavy. CLSN shares closed Monday at $2.02 and gapped up to open this morning at $2.63 on the biotech company’s update regarding its Phase 1b dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer followed by interval debulking surgery.

NASDAQ:CLSN
Daily candle bar graph

Founded in 1982, Celsion Corporation develops and directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. Celsion Corporation (NASDAQ:CLSN)’s lead product candidate, ThermoDox, is in Phase 3 clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. Celsion Corporation (NASDAQ:CLSN) is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.

According to Celsion Corporation (NASDAQ:CLSN)’s press release:

  • Of the fourteen patients treated to date, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate (DCR) and an 86% objective response rate (ORR).
  • Of the five patients treated in the highest dose cohort, there was a 100% objective response rate with one (1) complete response and four (4) partial responses.
  • Fourteen patients had successful resections of their tumors, with nine (9) patients (64%) having an R0 resection, which indicates a margin-negative resection in which no gross or microscopic tumor remains in the tumor bed.
  • Of the five patients treated at the highest dose cohort, all five patients (100%) experienced a R0 surgical resection.
  • Of the seven patients who have received GEN-1 treatment over one year ago and are being followed, only one patient’s cancer has progressed after 11.7 months.

Celsion Corporation (NASDAQ:CLSN) is followed by three investment firms. Two analysts rate CLSN shares as a “Strong Buy” and one rates the shares as a “Hold”. Their consensus price target is over $15. CLSN shareholders have had their shares diluted every single year since 2012 when there were 550,000 shares outstanding. By 2016 that number had ballooned to 1.85 million. EPS losses have also been standard since 2012 when the company posted a loss of (-$48.11) per shares. In 2016 that loss shrank to (-$11.90).

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. All information, or data, is provided with no guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Celsion Corporation (NASDAQ:CLSN)

Shareholders Hit Again by Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5.4 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direct offering. The market responded by punishing the shares, dropping almost 24%. CLSN shares ended yesterday at $3.20 but after the news of the share dilution hit the streets, sellers took over and CLSN closed the day at $2.44. Volumes were double their 30-day, daily averages.

Celsion Corporation (NASDAQ:CLSN) agreed to sell an aggregate of approximately 2 million shares of common stock, or pre-funded warrants in lieu thereof, at a price of $2.75 per common share or warrant share, respectively, in the registered direct offering.   Additionally, the investors will receive, for each share of common stock or pre-funded warrant purchased in the registered direct offering, a Series AAA warrant to purchase one (1) share of common stock and a Series BBB warrant to purchase one (1) share of common stock. The Series AAA warrants have an exercise price of $2.75 per share, are initially exercisable six months following issuance, and terminate five and one-half years following issuance. The Series BBB warrants have an exercise price of $8.00 per share, are immediately exercisable, and terminate one year following issuance.

Celsion Corporation (NASDAQ:CLSN) is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. The company has a poor history with their shareholders. In 2012, shareholders experienced an EPS loss of (-$48.11). That was followed by losses of (-$13.29), (-$19.32), (-$14.42), and, in 2016, (-$11.90). Meanwhile, the number of shares outstanding has increased every year since 2012 when Celsion Corporation (NASDAQ:CLSN) reported 0.55 million shares. Unfortunately that number had steadily increased and by 2016 the number of outstanding shares was reported at 1.85 million.

Performance has not been attractive. Celsion Corporation (NASDAQ:CLSN) are down over 42% YTD, down over 65% for the past six months, and down over 86% for the year.

Despite the poor performance, two analysts rank Celsion Corporation (NASDAQ:CLSN) shares as a “Strong Buy” and one ranks CLSN shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Abeona Therapeutics Inc (NASDAQ:ABEO)

Celsion Corporation (NASDAQ:CLSN) Explodes On Positive Ovarian Cancer Trial Results

Celsion Corporation (NASDAQ:CLSN)

Shares of Celsion Corporation (NASDAQ:CLSN) exploded in the market after the cancer-drugs developer said its candidate drug for ovarian cancer showed promising findings in early-stage trials. The $20 million biotech company says a Phase 1b study of Gen-1 as a standard care for patients with advanced ovarian cancer demonstrated a 100% disease control rate with an 86% objective response rate.

Gen-1 Positive Results

In the OVATION study, Gen-1, in combination with standard chemotherapy, produced positive results according to the company with no dose limiting toxicities. In a poster presentation at the American Society of Clinical Oncology, Celsion Corporation (NASDAQ:CLSN) says two of the 14 patients under treatment demonstrated a complete response. Ten patients, on the other hand, demonstrated partial response with two demonstrating stable diseases.

Fourteen patients had successful resections of their tumors with nine patients showing R0 resection. All patients also experienced a significant decrease in CA-125 protein according to the biopharmaceutical company.

“The translational research data in the poster presentation demonstrates that GEN-1 is producing beneficial cytokines and positively impacting T-cells in the tumor. This is strong early data and we believe that GEN-1 may be stimulating the immune system to improve tumor control in these patients. I am looking forward to continuing our clinical evaluation of GEN-1 in subsequent ovarian cancer studies,” said Dr. Premal Thaker.

In view of the encouraging clinical results, Celsion Corporation (NASDAQ:CLSN) is planning to evaluate GEN-1 in combination with Avastin in the 2nd line. The company is also exploring the possibility of continuing the clinical trials in an underserved patient population.

Reverse Stock Split

Separately Celsion Corporation (NASDAQ:CLSN) has carried out a 1:14 reverse split of its common stock in what is seen as an effort to reduce over dilution. The number of outstanding shares were reduced to about 4.1 million from 56,982,418. The reverse stock split was approved by the company’s shareholders at the annual general meeting last month. Celsion Corporation (NASDAQ:CLSN) hopes the reverse split will make the common stock attractive to institutional investors – especially after the recent positive clinical trials.

Celsion Corporation (NASDAQ:CLSN) stock was up by 24.06% in Monday’s trading session on the positive Gen-1 news, and ended the day at $3.30 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica Grey has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.